Condition
Pirfenidone
Total Trials
4
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 2 (1)
P 3 (1)
P 4 (2)
Trial Status
Unknown4
Clinical Trials (4)
Showing 4 of 4 trials
NCT06142318Phase 2Unknown
Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma
NCT04928586Phase 4UnknownPrimary
Immunosuppressant Combined With Pirfenidone in CTD-ILD
NCT05505409Phase 4UnknownPrimary
Efficacy and Safety of Pirfenidone in CTD-ILD
NCT04282902Phase 3Unknown
A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection
Showing all 4 trials